Skip to main content

Table 3 SF-36 domain scores and SF-6D utility scores (ITT population)

From: Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

 

A/G norms

TCZ-QW + Pred-26

N = 100

PBO + Pred-26

N = 50

PBO + Pred-52

N = 51

      

p value

   

p value

BL

Wk 52

LSM Δ BL–Wk 52

BL

Wk 52

LSM Δ BL–Wk 52

TCZ-QW + Pred-26 vs PBO + Pred-26

BL

Wk 52

LSM Δ BL–Wk 52

pTCZ-QW + Pred-26 vs PBO + Pred-52

PF

67.56

69.10

n = 100

78.28

n = 85

6.83

n = 98

63.60

n = 50

63.48

n = 43

− 3.43

n = 49

0.0024

59.40

n = 50

65.44

n = 45

2.68

n = 50

NS

RP

69.44

49.56

n = 100

73.75

n = 85

20.64

n = 98

52.42

n = 49

58.28

n = 43

5.87

n = 48

< 0.001

45.38

n = 50

53.89

n = 45

4.46

n = 50

< 0.001

BP

64.52

61.93

n = 100

73.25

n = 85

10.89

n = 98

58.90

n = 50

61.77

n = 43

1.00

n = 49

NS

55.67

n = 49

56.27

n = 45

− 2.87

n = 49

< 0.001

GH

66.49

55.00

n = 97

65.81

n = 85

9.06

n = 95

56.43

n = 49

57.28

n = 43

− 1.34

n = 48

< 0.001

55.69

n = 50

52.29

n = 45

− 4.05

n = 50

< 0.001

VT

58.65

50.19

n = 99

66.13

n = 85

15.69

n = 97

49.00

n = 50

55.67

n = 43

5.26

n = 49

0.0011

42.38

n = 50

49.17

n = 45

3.53

n = 50

< 0.001

SF

81.49

64.25

n = 100

84.71

n = 85

17.35

n = 98

65.25

n = 50

75.87

n = 43

9.83

n = 49

NS

63.00

n = 50

67.50

n = 45

2.34

n = 50

< 0.001

RE

82.08

66.38

n = 100

82.45

n = 85

13.37

n = 98

64.63

n = 49

74.81

n = 43

6.44

n = 48

NS

60.33

n = 50

69.63

n = 45

3.53

n = 50

NS

MH

77.16

64.04

n = 99

77.94

n = 85

12.54

n = 97

64.20

n = 50

73.60

n = 43

7.43

n = 49

NS

59.10

n = 50

66.33

n = 45

3.13

n = 50

< 0.001

SF-6D utility score

0.746

0.694

0.775

0.080

0.686

0.721

0.034

0.663

0.692

0.029

  1. Changes meeting or exceeding the MCID of 5.0 for domain scores and meeting or exceeding the MID of 0.041 for SF-6D scores (based on patients with RA and SLE) are shown in italics
  2. A/G age/gender, BL baseline, BP bodily pain, GH general health, ITT intent-to-treat, LSM least squares mean, MH mental health, NS not significant (p > 0.01), PBO placebo, PF, physical function, QW every week, RE role emotional, RP role physical, SF social function, SF-36 36-Item Short-Form Health Survey, SLE systemic lupus erythematosus, TCZ tocilizumab, VT vitality, wk week